Zygosity

Kraig Biocraft Laboratories Establishes Homozygosity and Confirms BAM 1 Hybrid Optimized Ahead of Spring Production Trials

Retrieved on: 
Tuesday, February 27, 2024

Establishing homozygosity for the targeted gene in both parental strains means that the Company's new BAM 1 hybrid production system is optimized for recombinant spider silk production.

Key Points: 
  • Establishing homozygosity for the targeted gene in both parental strains means that the Company's new BAM 1 hybrid production system is optimized for recombinant spider silk production.
  • The BAM 1 hybrid represents the Company's latest innovation in the commercialization of recombinant spider silk technology.
  • Achieving homozygosity for both BAM 1 parental strains is another significant milestone in the commercialization of recombinant spider silk.
  • "Our team set an aggressive deadline for achieving homozygosity in the BAM 1 hybrid ahead of our spring production trials," said CEO and Founder, Kim Thompson.

Global High Resolution Melting Research Report 2023: Market to Reach $385.6 Billion by 2030 - Clinical Diagnostics be the Fastest-growing Segment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023

The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global high resolution melting analysis market size is expected to reach USD 385.6 billion by 2030, growing at a CAGR of 3.32% from 2023 to 2030
    Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.
  • Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach.
  • The drug kalydeco was approved for patients reported to have a specific genetic mutation known as "G551D mutation.

Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis

Retrieved on: 
Friday, November 10, 2023

Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.

Key Points: 
  • Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.
  • “IriSight™ CNV Analysis provides the first true alternative to CMA,” said Dr. Allan J. Fisher, FACOG, FACMG, Variantyx Medical Director.
  • “Because the entire genome is sequenced, a broader range of chromosomal abnormalities are detected by the test including aneuploidy, unbalanced rearrangements, inversions, deletions/duplications, copy number variants (CNVs), regions of homozygosity and possible uniparental disomy.
  • Variantyx’s proprietary whole genome-based platform enables detection of a wider range of chromosomal abnormalities, not just matching but exceeding the capabilities of traditional CMA.

First Tunisian study examining age of onset for biallelic mutations in Huntington's disease

Retrieved on: 
Sunday, August 27, 2023

This Tunisian cohort study reported that the age of disease onset for patients with a homozygous mutation in the Huntingtin gene (HTT) did not differ significantly from that of heterozygous patients.

Key Points: 
  • This Tunisian cohort study reported that the age of disease onset for patients with a homozygous mutation in the Huntingtin gene (HTT) did not differ significantly from that of heterozygous patients.
  • The age of disease onset between the homozygous and heterozygous patients did not differ significantly.
  • Patients with smaller all were associated with a later age of onset, 62 years for homozygous and 74 years for heterozygous.
  • The number of CAG repeats and age of disease onset was shown to be inversely correlated for homozygous patients.

STRmix Limited Launches Completely New Version of FaSTR DNA

Retrieved on: 
Wednesday, July 6, 2022

WASHINGTON, July 6, 2022 /PRNewswire-PRWeb/ -- STRmix Limited has released a completely new version of FaSTR™ DNA containing major updates which further strengthen the expert forensic software's ability to rapidly analyze DNA profiles and assign a Number of Contributors (NoC) estimate.

Key Points: 
  • Expert Forensic Software Seamlessly Integrates with STRmix for Greater Speed, Efficiency
    WASHINGTON, July 6, 2022 /PRNewswire-PRWeb/ -- STRmix Limited has released a completely new version of FaSTR DNA containing major updates which further strengthen the expert forensic software's ability to rapidly analyze DNA profiles and assign a Number of Contributors (NoC) estimate.
  • FaSTR DNA seamlessly integrates with STRmix (when in use) for even greater speed and efficiency in analysis and interpretation of complex mixed DNA profiles.
  • FaSTR DNA works by applying a set of fully configurable rules to analyze most DNA profiles automatically.
  • Where the intervention of a DNA analyst is required, FaSTR DNA readily provides all details related to possible ambiguity of a peak (i.e.

I Peace accelerates allogeneic iPSC-derived cell therapies with g high throughput method to identify a large number of donors with specific HLA haplotypes.

Retrieved on: 
Wednesday, May 11, 2022

With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs.

Key Points: 
  • With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs.
  • Unlike conventional methods of identifying specific potential donors that yield only a handful of matches at best, this process can help identify a large number of potential donors with high efficiency.
  • We sequenced 98 HLA loci by high-resolution, next-generation sequencing-based HLA haplotyping from seven people, and found that the algorithm accuracy was above 93%.
  • I Peace's mission is to ease the suffering of diseased patients and help healthy people maintain a high quality of life.

LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, May 3, 2022

This year we are presenting important preclinical data supporting our most advanced cardiovascular gene therapy programs in FA and ARVC, said Nolan Townsend, Chief Executive Officer of LEXEO.

Key Points: 
  • This year we are presenting important preclinical data supporting our most advanced cardiovascular gene therapy programs in FA and ARVC, said Nolan Townsend, Chief Executive Officer of LEXEO.
  • The advances in these programs and others will help bolster our leadership position in the cardiovascular gene therapy category.
  • Four abstracts, including two oral presentations, were selected for ASGCT.
  • Study researchers hypothesized that PKP2 protein dose is a critical driver of ARVC, and that PKP2 gene therapy via AAV strategies can prevent and rescue ARVC development.

Oakland Police Department Begins Using FaSTR DNA in Criminal Investigations

Retrieved on: 
Wednesday, March 9, 2022

WASHINGTON, March 9, 2022 /PRNewswire-PRWeb/ --As of January 10, 2022, the Oakland (CA) Police Department Crime Laboratory began using FaSTR DNA, expert forensic software that rapidly analyzes DNA profiles, in its criminal investigations.

Key Points: 
  • WASHINGTON, March 9, 2022 /PRNewswire-PRWeb/ --As of January 10, 2022, the Oakland (CA) Police Department Crime Laboratory began using FaSTR DNA, expert forensic software that rapidly analyzes DNA profiles, in its criminal investigations.
  • The Oakland Police Department (OPD) services the community of Oakland, CA.
  • DNA Technical leadership worked with ESR to validate FaSTR DNA methods for use in casework.
  • For more complex DNA analyses in which the intervention of a DNA analyst is required, FaSTR DNA provides all details related to possible ambiguity of a peak (i.e.

Presentation at ASHG Showcases New Capabilities for Optical Genome Mapping with Detection of Allelic Imbalance and Absence of Heterozygosity Further Expanding Its Utility in Revealing More Clinically Relevant Variants

Retrieved on: 
Wednesday, October 20, 2021

These new OGM capabilities are expected to be released to Bionanos customers in upcoming versions of our Access and Solve software.

Key Points: 
  • These new OGM capabilities are expected to be released to Bionanos customers in upcoming versions of our Access and Solve software.
  • For example, some regions with AOH may be indicative of uniparental isodisomy (UPD) or regions of the genome identical by descent (IBD).
  • Measurement and representation of allelic imbalance enables OGM to detect triploidy and other chromosomal imbalances and may shed light on mosaic SVs.
  • We believe the detection of triploidy, regions associated with imprinted chromosomal disorders and IBD substantially improves the utility of OGM for clinical research applications.

Versiti Launches HLA Loss of Heterozygosity Evaluation

Retrieved on: 
Tuesday, October 12, 2021

MILWAUKEE, Oct. 12, 2021 /PRNewswire/ -- Versiti, Inc., one of the nation's leading blood health and research organizations, today announced a new test for detecting and characterizing genomic loss of heterozygosity (LOH) in the Human Leukocyte Antigen (HLA) region.

Key Points: 
  • MILWAUKEE, Oct. 12, 2021 /PRNewswire/ -- Versiti, Inc., one of the nation's leading blood health and research organizations, today announced a new test for detecting and characterizing genomic loss of heterozygosity (LOH) in the Human Leukocyte Antigen (HLA) region.
  • Groundbreaking test helps detect and characterize genomic loss of heterozygosity in the HLA region.
  • Under the direction of Jennifer Schiller Ph.D., D(ABHI), the Versiti Histocompatibility Lab has created a comprehensive evaluation to detect genomic loss of heterozygosity specifically for transplant patients.
  • "We expect that our HLA Loss of Heterozygosity evaluation test will provide valuable information to physicians, enabling them to make better-informed decisions during post-transplant disease relapse, potentially giving patients better outcomes," said Dr. Matthew Anderson, VP and medical director, Versiti Diagnostic Laboratories.